Novel Intravaginal Drug Delivery System Based on Molecularly PEGylated Lipid Matrices for Improved Antifungal Activity of Miconazole Nitrate

Figure 6

Time-resolved stability of MN-SLMs (A₀–AM₃) batches (a), MN-SLMs (B₀–BM₃) batches (b), MN-SLMs (C₀–CM₃) batches (c), and MN-SLMs (D₀–DM₃) batches (d) at room temperature. Key: batches A₀ and AM₁–AM₃ are non-PEGylated SLMs; batches B, C, and D are PEGylated SLMs containing increasing concentrations (1.0, 2.0, and 4.0 %w/w) of PEG 4000, respectively; – are unloaded SLMs while batches –, –, and – contain increasing concentrations (1.0, 2.0, and 3.0 %w/w) of miconazole nitrate, respectively.

(a)

(b)

(c)

(d)